A Phase 3 interventional study of teduglutide and placebo in Short Bowel Syndrome, sponsored by Shire. Completed at 35 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-03.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.
Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 2nd largest by enrollment, is the only one that started in 2008, is one of 16 in phase 3, and was the 3rd registered.
159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.
Browse Short Bowel Syndrome studies →1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country. Recruiting first, the newest first:
Meyer Children's Hospital IRCCS · Sites in Italy
Ages 4 mo–17 yrs
By country, each count listing its studies:
teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2008.
This study's enrollment of 86 is above the median of 21 across 108 interventional studies indexed under Short Bowel Syndrome.
Median enrollment 20 across the 20 interventional studies. Of the 18 that completed or were terminated, 16 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 20 have an industry lead sponsor. The 6 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
26 studies in Short Bowel Syndrome by Takeda: 1 open now, 3 under way, 1 of them phase 3. Of 23 finished, 16 (70%) have results posted.
Among the 26 studies in Short Bowel Syndrome by Takeda, this one is the 2nd largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2008, is one of 17 in phase 3, and was the 3rd registered.
Takeda’s Short Bowel Syndrome studies by the year they started, since 2004.
1 of the studies testing teduglutide in Short Bowel Syndrome that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06973304Phase 3TakedaA Study of Teduglutide in Chinese Adults With Short Bowel Syndrome | 2027-02-10 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing teduglutide in Short Bowel Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 26 in Short Bowel Syndrome:
This tab as a report to print or save as PDF → With an account.
Teduglutide is an investigative medicine being evaluated as a possible treatment for people with parenteral nutrition (PN) dependent Short Bowel Syndrome (SBS). Teduglutide is similar to a protein the body makes. When people have SBS, their bodies do not make enough of the protein and they have trouble getting nutrients and fluids from the food they eat and drink. This study was designed to provide evidence of efficacy, safety, and tolerability of teduglutide 0.05 mg/kg daily in SBS subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.05 mg/kg/day sc dose of teduglutide
Drug: teduglutide
Matching subcutaneous dose of placebo to teduglutide
Drug: placebo
0.05 mg/kg/day sc injection for 24 weeks
Also known as: GATTEX, ALX-0600
Matching daily subcutaneous dose of placebo to teduglutide for 24 weeks
Responder
Comparison of subjects treated with teduglutide to placebo who achieve a 20 to 100% reduction from baseline in weekly parenteral nutrition/intravenous fluid (PN/I.V.) volume at weeks 20 and 24.
Time frame: Weeks 20 and 24
Absolute Change in PN/I.V. Volume From Baseline to Last Time Point
Absolute change in the volume of PN/I.V. from baseline (Week 0) to the visit when the last data point was collected (week 4 through week 24, or earlier if the subject discontinued early).
Time frame: Week 0 to last visit when data was collected.
First Patient Screened - November 25, 2008; Last Patient Screened - July 13, 2010; First Patient Randomized - March 3, 2009; Last Patient Randomized - July 22, 2010; Locations - hospitals and transplant centers; Subjects must be on parenteral nutrition (PN) and/or intravenous (I.V.) fluids.
| Milestone | Teduglutide | Placebo |
|---|---|---|
| Started | 43 | 43 |
| Discontinued during dosing period | 4 | 4 |
| Completed | 39 | 39 |
| Not completed | 4 | 4 |
| Withdrew: Adverse event | 2 | 3 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Randomized in error by site | 1 | 0 |
Comparison of subjects treated with teduglutide to placebo who achieve a 20 to 100% reduction from baseline in weekly parenteral nutrition/intravenous fluid (PN/I.V.) volume at weeks 20 and 24.
| subjects | Teduglutide | Placebo |
|---|---|---|
| Responder | 27 | 13 |
Absolute change in the volume of PN/I.V. from baseline (Week 0) to the visit when the last data point was collected (week 4 through week 24, or earlier if the subject discontinued early).
| Liters/Week | Teduglutide | Placebo |
|---|---|---|
| Absolute Change in PN/I.V. Volume From Baseline to Last Time Point | -4.28 ± 3.81 | -2.38 ± 2.79 |
Collected over Adverse event data were collected for each subject from the time informed consent was signed to end of study. For this reporting of adverse event, the most commonly reported treatment emergent adverse events (>=3 subjects at SOC level) are listed.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Teduglutide | — | 15/42 (35.7%) | 35/42 (83.3%) |
| Placebo | — | 12/43 (27.9%) | 34/43 (79.1%) |
| Event | Teduglutide | Placebo |
|---|---|---|
| Catheter-related infectionInfections and infestations | 5/42 | 1/43 |
| BacteremiaInfections and infestations | 0/42 | 3/43 |
| Central line infectionInfections and infestations | 2/42 | 3/43 |
| Urinary tract infectionInfections and infestations | 2/42 | 1/43 |
| Device dislocationInjury, poisoning and procedural complications | 0/42 | 2/43 |
| Adenovirus infectionInfections and infestations | 1/42 | 0/43 |
| Catheter sepsisInfections and infestations | 1/42 | 0/43 |
| Catheter-related complicationGeneral disorders | 1/42 | 0/43 |
| Cholecystitis acuteHepatobiliary disorders | 1/42 | 0/43 |
| DehydrationMetabolism and nutrition disorders | 1/42 | 0/43 |
| Event | Teduglutide | Placebo |
|---|---|---|
| Abdominal painGastrointestinal disorders | 13/42 | 10/43 |
| NauseaGastrointestinal disorders | 12/42 | 8/43 |
| Gastrointestinal stoma complicationInjury, poisoning and procedural complications | 10/42 | 3/43 |
| Abdominal distensionGastrointestinal disorders | 9/42 | 1/43 |
| Central line systemic infectionsInfections and infestations | 7/42 | 7/43 |
| Edema peripheralGeneral disorders | 7/42 | 2/43 |
| Urinary tract infectionInfections and infestations | 6/42 | 4/43 |
| FlatulenceGastrointestinal disorders | 5/42 | 3/43 |
| VomitingGastrointestinal disorders | 5/42 | 4/43 |
| DiarrheaGastrointestinal disorders | 3/42 | 5/43 |
| Age, Continuous(years) | Teduglutide | Placebo | Total |
|---|---|---|---|
| Mean | 50.9 ± 12.6 | 49.7 ± 15.6 | 50.3 ± 14.1 |
| Sex: Female, Male(Participants) | Teduglutide | Placebo | Total |
|---|---|---|---|
| Female | 22 | 24 | 46 |
| Male | 21 | 19 | 40 |
Ran from Nov 2008 to primary completion in Jan 2011, 26 months.
Results were first posted in Feb 2012, 1 year after primary completion.
Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 26 months is below that.
Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Teduglutide